Drug intelligence / Profile preview

alprazolam + valproate

Development stage
Unknown
Lead developer
Pfizer
Modality
Small Molecules
Administration
Oral, Intravenous, Sublingual, Rectal
01

Overview

Alprazolam + valproate is a combination of two pharmaceutical drugs, each with distinct mechanisms of action. Alprazolam is a benzodiazepine that acts as a central nervous system depressant by binding to γ-aminobutyric acid (GABA) type-A receptors in the brain, enhancing their inhibitory effect on neurotransmission. It is primarily used for the treatment of anxiety disorders and panic disorder[3][9][10]. Valproate (valproic acid or its salt forms such as valproate sodium) is an anticonvulsant and mood stabilizer that increases brain concentrations of gamma-aminobutyric acid (GABA), thereby exerting antiepileptic, antimigraine, and mood-stabilizing effects[4][6][8]. The combination may be considered in clinical scenarios where both anxiolytic/sedative effects (from alprazolam) and anticonvulsant/mood stabilization (from valproate) are desired; however, this combination carries an increased risk for central nervous system depression due to pharmacokinetic interactions—valproic acid can decrease the metabolism of alprazolam leading to higher blood levels and increased side effects[1][2][7].

Other names
alprazolam and valproic acidalprazolam and valproate sodium
02

Targets

GABRR (GABA-A receptor subunit rho)ABAT (4-aminobutyrate aminotransferase)

Beyond the preview

Go deeper on alprazolam + valproate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on alprazolam + valproate.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call